Fill-finish Pharmaceutical Contract Manufacturing Market Size is Estimated to Witness 6.1% CAGR till 2030
The global Fill-finish Pharmaceutical Contract Manufacturing Market size is expected to reach USD 14.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.1% from 2022 to 2030. Increasing demand for drugs across the global market and the advantage of the reduction in the overall investment for developing drugs with contract manufacturing are the key factors driving the growth of the market. Contract fill-and-finish services are one of the most commonly outsourced services presently. Almost all pharmaceutical and biotech firms outsource at least some of their fill-and-finish requirements.
Unpredicted demand, second source policies, and better matching scale with need are all factors to consider when utilizing a CMO’s capacity. Highly specialized capabilities like prefilled syringes, lyophilization, and cartridges, as well as novel therapeutics, necessitate specialized manufacturing that is more cost-effective to outsource. Firms with in-house aseptic fill/finish capacity outsource 39% of their fill and finish requirements, according to contract pharma. Furthermore, filling accounts for 59% of the market, while lyophilization accounts for 24%.
However, the COVID-19 pandemic spurred the development of COVID-19 vaccines, antibody therapy, antiviral drugs, and a variety of other related pharmaceutical products. The pandemic severely impacted countries such as Brazil, India, the U.S., and major European countries, increasing demand for biopharmaceutical products and, as a result, drug production. Vaccines and biologics require special manufacturing and fill-finish equipment and procedures to ensure product quality and safety, necessitating advanced analytical competencies and adaptable aseptic fill-finish technologies. This resulted in the positive impact of covid-19 on the market.
Fill-finish Pharmaceutical Contract Manufacturing Market Report Highlights
- The large molecules segment dominated the market with a revenue share of 67.3% in 2021. Rising investment by pharmaceutical companies in R&D for large molecules and biosimilar would drive market growth
- The vials segment accounted for the largest revenue share of 52.9% in 2021. They are the most versatile and easy-to-use dosage form. It is observed that the vial filling reduces the product loss and maximizes yield
- Based on end-user, the biopharmaceutical companies segment accounted for the largest share of 54.9% in 2021. The increased demand for biopharmaceutical drugs, as well as funding for the biotech sector drive market growth
- Asia Pacific led the market in 2021 and is projected to witness the fastest CAGR of 6.3% during the forecast years due to the rising number of CMOs expanding in the region and a huge number of fill-finish facilities being constructed. For instance, Thermo Fisher would increase sterile filling capacity with a new facility in Singapore. The facility would then initially provide a high-speed sterilized line approved for live virus having to fill first large-scale expertise in Singapore followed by an additional feature for standard fill/finish